CanBas Co Ltd is a pharmaceutical bioventure company that specializes in drug discovery. They are dedicated to developing innovative treatments for cancer and other diseases. Their primary focus is on the development of a potential anti-cancer drug candidate called CBP501, which has shown promising results in clinical trials for the third-line treatment of pancreatic cancer.

CBP501 has demonstrated strong efficacy when combined with immune-based cancer drugs. CanBas Co Ltd is now preparing for Phase 2 trials with the goal of obtaining approval for CBP501. In addition to CBP501, CanBas Co Ltd has a second pipeline consisting of a reversible XPO1 inhibitor called CBS9106.

Under a licensing agreement, CBS9106 was acquired by Menarini, an Italian pharmaceutical company, presenting opportunities for global expansion. CanBas Co Ltd is actively engaged in research collaborations to develop next-generation clinical pipelines. They are conducting research on a dual IDO/TDO inhibition compound for potential use as a treatment for COVID-19.

They also focus on the development of personalized cancer treatments using genetic mutation analysis. By licensing their pipelines and minimizing development timelines, CanBas Co Ltd aims to ensure speedy delivery of their drugs to patients. They are committed to maximizing the long-term value of their research through aggressive and continuous investment in research and development.

As a biopharmaceutical venture, CanBas Co Ltd strives to provide high value to the pharmaceutical value chain and keep investors well-informed through thorough disclosure of information